The New Weapon In Ongoing Battle Between Drug Companies And Pharmacy Benefit Managers

Drugmakers are expecting to take a financial hit from the copay accumulator programs that PBMs have begun marketing. And the Supreme Court may review a whistleblower case that could have implications across the pharmaceutical industry.

from Kaiser Health News https://ift.tt/2vnZg0y